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1. Introduction 
The activation of plasminogen by trypsin-like plas- 
minogen activators constitutes a widespread mecha- 
nism for generating localized extracellular proteolysis 
[ 11. Plasminogen activators exist in several molecular 
forms that can be distinguished on the basis of their 
M,-values and their susceptibility to inhibition by 
antibodies against the normal urinary enzyme, uroki- 
nase [2]. Differences between tissue and urinary acti- 
vators concerning their binding affinities towards cer- 
tain synthetic substrates [3] and their susceptibility 
to inactivation by peptidyl chloromethylketone inhib- 
itors [4] have also been reported. The nature of the 
relationship that exists between the multiple forms of 
plasminogen activators (products of different genes or 
forms derived by partial proteolysis of a common pre- 
cursor) is of constant concern. Peptide maps of these 
proteins would contribute to answer this question 
unequivocally. 
The well-characterized human urinary plasminogen 
activator, urokinase (EC 3.4.99.26) has been chosen 
in this study and its peptide map is presented. To 
identify the peptides containing the amino acid resi- 
dues of the active site, peptide maps of the enzyme 
modified by 3,4-dihydro-3,4-dibromo&bromomethyl- 
coumarin (scheme) are reported. This bifunctional 
reagent possesses a reactive ster bond with a cis con- 
figuration and an alkylating function which appears 
after hydrolytic cleavage of the ester bond [5]. Some 
proteases have been reported to be inactivated by this 
reagent [6,7]: histidine-57 was preferentially modi- 
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fied by the activated alkylating function generated in
the active site of achymotrypsin [8]. 
2. Materials and methods 
Human urokinase (RFU 810) was a kind gift from 
Choay, France. Its concentration i solution was 
determined by the amido black procedure [9] using 
bovine serum albumin as standard. Active site titra- 
tions were carried out with p-nitrophenyl-p’-guanidi- 
nobenzoate as in [lo]. Sodium dodecylsulfate (SDS)- 
polyacrylamide gel electrophoresis was performed 
using 12.5% polyacrylamide slab gels according to 
[ 111. Gels were scanned with a Joyce densitometer 
at 500 nm. The 2 forms of urokinase (47 000 and 
33 OOOM,) were -9O-95% and 5--lo%, respectively. 
Their plasminogen activator activity was detected by 
electrophoretic analysis in SDS-polyacrylamide gels 
containing copolymerized plasminogen and gelatin 
[ 121. The final concentrations were : 0.125 M Tris 
(stacking el), 0.05% (w/v) gelatin and 40 c(g human 
plasminogen/ml. The activity was nearly exclusively 
localized in a band of app. Mr 47 000. 
Pepsin was a twice-crystallized product, purchased 
from Worthington Biochemicals; cu-CBZ-Glysine-p- 
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nitrophenylester and 6-methylcoumarin were obtained 
from Sigma and Schuchardt, respectively. Standard 
chemicals were from Merck, Fluka and Sigma. 
2.1. Reparation of 3,4_dihydro-3,4_dibromo-&bromo- 
methylcoumarin 
The reagent was prepared and characterized as in 
[6]. The radioactive 3,4dihydro-3,4dibromod- 
bromo-[ 3H]methylcoumarin synthesized according to 
[ 131 was obtained with a spec. act. 5.5 $i/mmol. 
2.2. Kinetic analysis 
The esterase activity of the enzyme derivatives was 
determined towards cu-CBZ-Llysine-p-nitrophenyl 
ester according to [14] using a Car-y model 15 spec- 
trophotometer. For native enzyme, the conditions 
employed were: 7.4 X 10e8 M enzyme, 0.1 M sodium 
phosphate buffer (pH 6.8), 0.1 M NaCl, 2 X lo4 M 
cu-CBZ-Llysine-p-nitrophenyl ester, 25°C. The 
increase in absorbance was monitored at 360 nm 
using E = 6.6 X lo3 MS1 . cm-’ [ 151. The initial veloc- 
ities were corrected for the spontaneous hydrolysis of 
the ester. All kinetic data were calculated on the basis 
of molarity of active sites, or percentage of active 
enzyme, as determined byactive site titration. 
2.3. Reactions with 3,4dihydro-3,4dibromo-6- 
bromomethylcoumarin 
2.3.1. Kinetics of inactivation 
The following general protocol was employed for 
the determination of the rate of enzymatic inactiva- 
tion. At time zero, 3,4-dihydro3,4-dibromo-6-bromo- 
methylcoumarin (final cont. 9.5-147 PM) was added 
in 10 s to a solution of urokinase (4.9 PM) in a 0.1 M 
sodium phosphate buffer, 0.1 M NaCl (pH 6.8) at 4°C 
or 25°C. Aliquots (15 fl) were removed at intervals and 
assayed for remaining enzymatic activity by addition 
to 1 ml appropriate standard assay mixture (see above). 
The apparent pseudo-first-order rate constants k 
were obtained from least-squares analysis of se Jpp 
plots of % remaining activity against time. 
2.3.2. Estimation of bound 3H-labehed groups 
Urokinase (0.7 nmol) was treated for 10 min with 
a 20.fold molar excess of 3 Pdihydro-3,4dibromo-6- 
bromomethyl[ 3H]coumarin under the above condi- 
tions (25’C). The reaction mixture was immediately 
filtered through a 0.2 I.cm cellulose acetate membrane 
(Schleicher and Schtill) whose radioactivity was mea- 
sured. In some experiments, the enzyme was incu- 
bated in the presence of 18 PM p-nitrophenyl-p’- 
guanidinobenzoate before treatment with the labelled 
reagent. 
2.4. Peptide maps 
A sample of 0.7 mg native or modified urokinase 
(treated with the labelled reagent as in section 2.3.2) 
was filtered through a celluloseacefate membrane 
and washed extensively. The enzyme on the mem- 
brane was digested with pepsin (0.07 mg) in 0.4 ml 
5% formic acid for 18 h at 37°C. After adjustment to 
pH 5 with pyridine, the reaction mixture was lyophil- 
ized. Aliquots containing -70 pg original urokinase in 
l-2 pl pyridine-water (50:50) were spotted onto a 
20 X 20 cm thin-layer chromatogram sheet (cellulose, 
F1440, Schleicher and Schtill). Chromatograms were 
carried out for 3 h in n-butanol-pyridine-acetic 
acid-water, 30:20:6:24 (by vol.). The plates were 
then exposed for 2 h at room temperature to per- 
formic acid vapors [ 161. After drying, electrophoresis 
in the second dimension was done at 400 V for 1.5 h 
at pH 2 (2% formic acid-8% acetic acid, v/v) using a 
double chamber Desaga pparatus. The peptides were 
detected with the cadmium-ninhydrin reagent [171 
or with 0.01% (w/v) fluorescamme in acetone (after 
spraying with 5% (v/v) triethylamine in acetone) [181 
and those containing histidine with the Pauly reagent 
[ 191. Labelled peptides were located by fluorography 
(EN3HANCETMSpray, New England Nuclear; Kodak 
X-Omat X-Ray Film, exposures from 4-10 days after 
flash activation [20]). Any background radioactivity 
due to residual reagent or to its hydrolysis products 
was determined bypeptide mapping in similar condi- 
tions. 
3. Results 
3,4-Dihydro-3,4-dibromo-6-bromomethylcoumarin 
is a time-dependent i activator of urokinase (Bg.1). 
The residual activity observed at the end of the reac- 
tion depends on the molar ratio f inhibitor to 
enzyme. With a 30-fold molar excess, the activity of 
urokinase was inhibited >90% of the initial level 
within 3 mm. In all cases, the activity losses followed 
pseudo-first-order kinetics characterized by the rate 
constants k,,, . These rate constants were propor- 
tional to the inhibitor concentration at low concen- 
trations (fig.1) and displayed atendency to level off 
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Fig.1. Kinetics of inactivation of urokinase (4.9 PM) by 
9.0 PM (a), 15.2 PM (a), 49.8 PM (0) and 99.6 NM (0) 
3,4dihydro-3,4dibromo-6-bromomethylcoumarin at pH 6.8 
in 0.1 M phosphate buffer and 0.1 M NaCl at 25°C. The activ- 
ity was determined against orCBZ-L-lysine-p-nitrophenyl- 
ester at pH 6.8 and 25°C for native and treated enzyme. The 
activity of the native enzyme was taken equal to 100. 
at higher concentrations (not shown). At 25’C, the 
experimental second-order rate constant obtained by 
dividing k,, by the inhibitor concentration isequal 
to 1.25 X lo4 M-r. min-’ (kapp/[I] -3.2 X lo2 M-l. 
min-’ at 4°C). No reactivation was observed after an 
incubation period of 8 h at 4°C. In the same condi- 
tions, the spontaneous loss of activity of a control 
sample was GO%. It was verified that the hydrolysis 
products of the reagent are inactive towards urokinase. 
Fig.2. Two-dimensional peptide maps: (A,B) peptide maps 
after ninhydrin staining of native (A) and modified (B) uroki- 
nase; (-+l and ‘2) the peptide which disappeared and the 
peptide which appeared upon reaction with 3,4-dihydro-3,4- 
dibromod-bromomethylcoumarin, respectively; (C) tracing 
of maps. Peptides containing histidine are hatched. The black 
spot represents the radioactive peptide. The positions of cys- 
teic acid, aspartate, leucine, histidine and arginine after elec- 
trophoresis are indicated. 
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Incubation experiments with the reagent labelled 
in the moiety expected to undergo covalent attach- 
ment to the enzyme showed that 1.2 + 0.1 equiv. 
[3H]aIkylating roup/m01 active enzyme was incor- 
porated. When the enzyme had been previously com- 
pletely inhibited by p-nitrophenyl-p’guanidinobenzo- 
ate which reacts with the active serine [21], a negligi- 
ble incorporation of the labelled reagent was observed 
(-0.1 equiv./mol protein). 
By peptide mapping, atypical position of the acidic 
peptide carrying the alkylated amino acid residue was 
accurately established (fig.2, j-2). Its alkylation is 
supported by the following facts: 
(0 
w 
The peptide maps of native and modified uroki- 
nase visualized by ninhydrin staining are depicted in 
flg.2. The main difference between both fingerprints 
lies in the disappearance (native urokhrase) of a Pauly- 
and ninhydrin-positive peptide (fig.2, +l), and the 
appearance (modified urokinase) of a new peptide 
(fig.2, +2) which was ninhydrin-positive and radioac- 
tive. Indeed, the autoradiogram of the peptide map 
obtained with urokinase modified by the labelled 
reagent displayed aunique spot which was superim- 
posed on the acidic peptide appearing after treatment 
with the reagent (tig.2, +2). No trace of radioactive 
material corresponding to the residual labelled reagent 
or hydrolysis products was detected. 
It is the only radioactive peptide after inactiva- 
tion by the tritiated reagent; 
Its position near the cathode agrees with t e pos- 
sible hydrolysis of the ester bond with active 
serine during peptide map treatments hus gener- 
ating a negatively charged carboxylate group. 
The alkylated peptide replaces aPauly-positive pep- 
tide present in the peptide map of native urokinase 
(fig.2, +l). This last result suggests hat a histidine 
residue in (or near) the active site might be modified. 
Indeed, urokinase is a serine protease [21] which can 
be related to serine proteases that depend upon the 
Asp...His... Ser triad for their catalytic action since 
direct evidence of a histidine residue in the active cen- 
ter was obtained [24]. It is noteworthy that both pep- 
tides 1 and 2 (fig.2) are located in a more acidic posi- 
tion than the corresponding peptides of native and 
modified trypsin examined in the same conditions 
(not shown). 
4. Discussion Adcnowledgements 
The inactivation of urokinase by 3,4dihydro3,4- 
dibromo-6-bromomethylcoumarin meets the criteria 
for active-site-directed, covalent enzyme inactivation 
[22] as supported by kinetic data, protection by 
p-nitrophenylp’guanidinobenzoate gainst inactiva- 
tion and stoichiometry of labelling by the radioactive 
reagent. Consequently, the main part of the inhibition 
is performed when the active serine is intact, suggest- 
ing a minimal reaction scheme analogous to that in 
[6,8] for the inactivation of achymotrypsin. After 
formation of the Michaelis complex, the enzyme is 
acylated on the active serine; in the transient acyl- 
enzyme, the reactive p-hydroxybenzylhalide is trans- 
formed into quinone methide which is instantaneously 
attacked either by any nucleophilic enzymic residue 
located in the vicinity (thus leading to covalent modi- 
fication) or by medium water (in this case, the 
enzyme is restored after deacylation). This scheme 
agrees with t e allcylation of a nucleophilic residue 
within (or near) the active site. The value obtained 
for kapp/[I] is smaller than that estimated for ar-chy- 
motrypsin [6]. Affinity labelling by peptides or argi- 
nine chloromethyl ketone are less effective [23]. 
We are greatly indebted to Professor M. Vilkas for 
a kind gift of 3,4dihydro-3,4dibromo-6bromomethh- 
ylcoumarin and for his help ln the synthesis of the 
labelled reagent. We express our thanks to A. L. 
Haenni for her interest and for carefully reading the 
manuscript. 
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